Soft tissue sarcoma, version 2.2012 featured updates to the NCCN guidelines

Margaret Von Mehren, Robert S. Benjamin, Marilyn M. Bui, Ephraim S. Casper, Ernest U. Conrad, Thomas F. DeLaney, Kristen N. Ganjoo, Suzanne George, Ricardo Gonzalez, Martin J. Heslin, John M. Kane, Joel Mayerson, Sean V. McGarry, Christian Meyer, Richard J. O'Donnell, I. Benjamin Paz, John D. Pfeifer, Raphael E. Pollock, R. Lor Randall, Richard F. RiedelScott Schuetze, Karen D. Schupak, Herbert S. Schwartz, Sridhar Shankar, Brian A. Van Tine, Jeffrey Wayne, Hema Sundar, Nicole R. McMillian

Research output: Contribution to journalReview articlepeer-review

114 Scopus citations

Abstract

The major changes to the 2012 and 2011 NCCN Guidelines for Soft Tissue Sarcoma pertain to the management of patients with gastrointestinal stromal tumors (GISTs) and desmoid tumors (aggressive fibromatosis). Postoperative imatinib following complete resection for primary GIST with no preoperative imatinib is now included as a category 1 recommendation for patients with intermediate or high risk of recurrence. The panel also reaffirmed the recommendation for preoperative use of imatinib in patients with GISTs that are resectable with negative margins but associated with significant surgical morbidity. Observation was included as an option for patients with resectable desmoid tumors that are small and asymptomatic, not causing morbidity, pain, or functional limitation. Sorafenib is included as an option for systemic therapy for patients with desmoid tumors.

Original languageEnglish
Pages (from-to)951-960
Number of pages10
JournalJournal of the National Comprehensive Cancer Network : JNCCN
Volume10
Issue number8
DOIs
StatePublished - Aug 1 2012

Fingerprint

Dive into the research topics of 'Soft tissue sarcoma, version 2.2012 featured updates to the NCCN guidelines'. Together they form a unique fingerprint.

Cite this